InvestorsHub Logo
Followers 32
Posts 10384
Boards Moderated 0
Alias Born 04/20/2016

Re: None

Thursday, 10/26/2017 10:32:49 AM

Thursday, October 26, 2017 10:32:49 AM

Post# of 1162
Bristol-Myers Squibb (BMY) Q3 results: Revenues: $5,254M (+6.7%); Net Income: $845M (-29.7%); EPS: $0.51 (-29.2%); Non-GAAP EPS: $0.75 (-2.6%); Quick Assets: $9,648M (+6.2%).
• Key Product Sales: Opdivo: $1,265M (+38%); Eliquis: $1,232M (+39%); Orencia: $632M (+10%); Sprycel: $509M (+8%); Yervoy: $323M (+13%); Hepatitis C Franchise: $73M (-81%); Baraclude: $264M (-14%).
• 2017 Guidance: EPS: $2.36 - 2.46 from $2.66 - 2.76; Non-GAAP EPS: $2.95 - 3.05 from $2.90 - 3.00.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News